Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Receivables for 14 consecutive years, with $281.1 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 26.77% to $281.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $281.1 million through Dec 2025, up 26.77% year-over-year, with the annual reading at $281.1 million for FY2025, 26.77% up from the prior year.
  • Receivables hit $281.1 million in Q4 2025 for Ani Pharmaceuticals, up from $252.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $281.1 million in Q4 2025 to a low of $91.9 million in Q1 2021.
  • Historically, Receivables has averaged $171.9 million across 5 years, with a median of $171.4 million in 2022.
  • Biggest five-year swings in Receivables: surged 62.35% in 2022 and later dropped 4.9% in 2023.
  • Year by year, Receivables stood at $128.5 million in 2021, then soared by 32.61% to $170.4 million in 2022, then dropped by 4.9% to $162.1 million in 2023, then skyrocketed by 36.8% to $221.7 million in 2024, then rose by 26.77% to $281.1 million in 2025.
  • Business Quant data shows Receivables for ANIP at $281.1 million in Q4 2025, $252.6 million in Q3 2025, and $225.7 million in Q2 2025.